Results at week 204
FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
Taltz maintained response through 204 weeks26
Induction period and open-label extension
In an mNRI analysis of patients receiving Taltz, PASI 75 results were 89% at week 60, 84% at week 108, 82% at week 156, and 83% at week 204. PASI 90 results were 78% at week 60, 71% at week 108, 69% at week 156, and 66% at week 204. PASI 100 results were 59% at week 60, 50% at week 108, 49% at week 156, and 48% at week 204.
SELECT IMPORTANT SAFETY INFORMATION
PRE-TREATMENT EVALUATION FOR TUBERCULOSIS
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.